These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 28379424)
1. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424 [TBL] [Abstract][Full Text] [Related]
2. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691 [TBL] [Abstract][Full Text] [Related]
3. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423 [TBL] [Abstract][Full Text] [Related]
4. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Vitucci M; Karpinich NO; Bash RE; Werneke AM; Schmid RS; White KK; McNeill RS; Huff B; Wang S; Van Dyke T; Miller CR Neuro Oncol; 2013 Oct; 15(10):1317-29. PubMed ID: 23814263 [TBL] [Abstract][Full Text] [Related]
5. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231 [TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway. Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479 [TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066 [TBL] [Abstract][Full Text] [Related]
10. Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide. Cheng HS; Chong YK; Lim EKY; Lee XY; Pang QY; Novera W; Marvalim C; Lee JXT; Ang BT; Tang C; Tan NS Neuro Oncol; 2024 Jul; 26(7):1247-1261. PubMed ID: 38366847 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260 [TBL] [Abstract][Full Text] [Related]
12. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. Ghosh JC; Siegelin MD; Vaira V; Faversani A; Tavecchio M; Chae YC; Lisanti S; Rampini P; Giroda M; Caino MC; Seo JH; Kossenkov AV; Michalek RD; Schultz DC; Bosari S; Languino LR; Altieri DC J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25650317 [TBL] [Abstract][Full Text] [Related]
13. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759 [TBL] [Abstract][Full Text] [Related]
14. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515 [TBL] [Abstract][Full Text] [Related]
15. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331 [TBL] [Abstract][Full Text] [Related]
16. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759 [TBL] [Abstract][Full Text] [Related]
17. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo. Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524 [TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related]
19. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. Pitts TM; Newton TP; Bradshaw-Pierce EL; Addison R; Arcaroli JJ; Klauck PJ; Bagby SM; Hyatt SL; Purkey A; Tentler JJ; Tan AC; Messersmith WA; Eckhardt SG; Leong S PLoS One; 2014; 9(11):e113037. PubMed ID: 25401499 [TBL] [Abstract][Full Text] [Related]
20. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Carra E; Barbieri F; Marubbi D; Pattarozzi A; Favoni RE; Florio T; Daga A Cell Cycle; 2013 Feb; 12(3):491-500. PubMed ID: 23324350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]